@entity5 irradiation augments the antitumor effect of cytokine-producing autologous @entity5 cell vaccines in a @entity19 XXXX model.

@entity2304 @entity137 @entity10191 @entity1313 @entity5 @entity19 @entity11 @entity777 @entity1961 @entity22618 @entity58 @entity637
The combined therapeutic effect of cytokine-producing @entity5 cell vaccines and local radiotherapy was studied in a @entity19 @entity11 261 (GI261) @entity1313 model. @entity1313 -bearing @entity19 were treated with cytokine ( @entity58 , @entity777 , @entity10191 , @entity2304 , @entity637 , @entity22618 , LT) producing vaccines made by in vitro transduction of GI261 cells with the corresponding adenoviral vectors. Vaccines producing either @entity58 or @entity2304 cured 20-40% of mice. The antitumor effect strongly depended on the secreted cytokine level. Vaccination therapy induced specific activation of cytotoxic T lymphocytes measured by cell-mediated @entity137 assay. @entity1313 were heavily infiltrated by @entity1961 + lymphocytes after treatment with @entity58 - or @entity2304 -secreting cells. @entity2304 vaccination induced moderate CD8+ infiltration, as well. Depleting either @entity1961 + or CD8+ lymphocyte subsets abolished the anticancer effect of @entity2304 -expressing cells. Strong synergism was observed by combining cytokine vaccination ( @entity2304 , @entity58 , IL-12) with @entity5 irradiation: about 80-100% of the @entity11 -bearing @entity19 was cured. The high efficiency of combined treatment was maintained even under suboptimal conditions when neither of the modalities cured any of the @entity19 alone. This suggests that vaccination therapy might open a new potential in the clinical treatment of high-grade @entity11 when applied as adjuvant to existing treatment modalities.
